Showing 4631-4640 of 7372 results for "".
- VYNE Therapeutics Completes Enrollment for Phase 2b Trial of VYN201 in Nonsegmental Vitiligohttps://practicaldermatology.com/news/vyne-therapeutics-completes-enrollment-phase-2b-trial-vyn201-nonsegmental-vitiligo/2470854/VYNE Therapeutics Inc. has finalized enrollment for its Phase 2b trial of VYN201, a once-daily topical gel for nonsegmental vitiligo, with initial data from the 24-week double-blind portion anticipated in mid-2025, according to a news release from the manufacturer. The randomized, double-b
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Castle Biosciences' Test Identifies AD Patients Likely to Achieve EASI90https://practicaldermatology.com/news/castle-biosciences-test-identifies-ad-patients-likely-achieve-easi90/2470795/Castle Biosciences has announced its investigational gene expression profile test for atopic dermatitis (AD) may identify patients likely to achieve a 90% or greater reduction in Eczema Area and Severity Index (EASI) scores within three months of targeted therapy initiation. Currently, ov
- Allergy-Friendly Detergents Safe for Atopic Dermatitis Patientshttps://practicaldermatology.com/news/allergy-friendly-detergents-safe-atopic-dermatitis-patients/2470779/A recent clinical study found that two laundry detergents marketed for sensitive skin do not negatively impact the skin microbiome or worsen symptoms of atopic dermatitis (AD). The study was conducted in 41 participants diagnosed with AD. For the present study, the researchers evaluated th
- Review: Potential and Challenges for Exosomes in Cosmetic Dermatologyhttps://practicaldermatology.com/news/review-potential-and-challenges-exosomes-cosmetic-dermatology/2470764/Exosomes show promise for enhancing skin and hair health, but key challenges must be addressed before they can be widely adopted in cosmetic dermatology, according to a new literature review in the Journal of Drugs in Dermatology. Exosomes, extracellular vesicles responsible for cellular c
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- Extended Analysis Confirms Favorable Safety for Upadacitinibhttps://practicaldermatology.com/news/extended-analysis-confirms-favorable-safety-upadacitinib/2470761/Results from a long-term integrated analysis support the favorable safety profile of upadacitinib for moderate-to-severe atopic dermatitis (AD) in adolescents and adults. The analysis, presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference, included over 9,000 patient-y
- ADapt Study: Lebrikizumab Improves Skin and Quality of Life in ADhttps://practicaldermatology.com/news/study-lebrikizumab-improves-skin-and-quality-life-ad/2470753/Results from the phase 3b ADapt study presented at the recent Revolutionizing Atopic Dermatitis (RAD) Conference indicated lebrikizumab (LEB) improved skin clearance, reduced itch, and enhanced quality of life in patients with moderate-to-severe atopic dermatitis (AD) in whom dupilumab (DUPI) was
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate